[Exploring new therapeutic approaches to the treatment of inflammatory disorders--lipoxins].
The prevalence of inflammatory disorders continues to increase and its optimal treatment still remains a challenge. Lipoxins, endogenous eicosanoids biosynthesised in vivo at inflammatory sites, are potent anti-inflammatory mediators. Therefore, it is of interest to investigate the potential effects of lipoxins that could attenuate chronic inflammation. Currently, only limited data on the effects of lipoxins in clinical investigations are available. Nevertheless, lipoxins caused inhibition of hyper-responsiveness and allergic airway inflammation in asthma. They could also impact the progression of inflammatory arthritides through the reduction of the inflammatory infiltrates and limiting tissue destruction. Lipoxins may play important anti-inflammatory roles in intestinal inflammation as well as in a number of cutaneous inflammatory disorders like psoriasis or atopic dermatitis. Taken together, the available data suggests that lipoxins may have broad therapeutic potential in inflammatory disorders and could provide an alternative to corticosteroids in certain clinical settings.